[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100640283":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":44,"collaborators":10,"id":46,"slug":47,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":48,"sex":54,"minAge":55,"maxAge":10,"enrollmentInfo":56,"targetDuration":10,"studyType":59,"phases":10,"briefSummary":60,"conditions":61,"keywords":64,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},{"fullName":5,"class":6},"Imelda GI Clinical Research Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"patient with IBD",null,"patient with Crohn or ulcerative colitis",[13],"Diagnostic Test: Leucine-rich α2-glycoprotein",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Leucine-rich α2-glycoprotein","Leucine-rich α2-glycoprotein measurement",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Peter Bossuyt","CONTACT","MD PhD","peter.bossuyt@imelda.be",[27],{"facility":28,"status":29,"city":30,"state":10,"zip":31,"country":32,"countryCode":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Imelda General Hospital","RECRUITING","Bonheiden","2820","Belgium","BE",{"type":35,"coordinates":36},"Point",[37,38],4.54714,51.02261,{"lat":38,"lon":37},[41],{"name":42,"role":23,"phone":43,"phoneExt":10,"email":25},"Peter Bossuyt, MD PhD","+3215505691",{"type":45,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100640283","leucine-rich-2-glycoprotein-correlation-with-clinical-endoscopic-and-histological-disease-activity-of-ibd-in-a-european-context-100640283",false,"NCT07621783","Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context","Leucine-rich α2-glycoprotein Correlation With Clinical, Endoscopic and Histological Disease Activity of IBD in a EuRopean Context: LEADER Trial.","LEADER","Inclusion Criteria:\n\n1. ≥18 years\n2. Patient with confirmed diagnosis of IBD\n3. Patient with planned endoscopy (ileocolonoscopy for Crohn's disease (CD)\u002Fulcerative colitis (UC) or sigmoidoscopy for UC) for the assessment of endoscopic disease activity according to routine practice\n4. willing to provide informed consent\n\nExclusion Criteria:\n\n1. Patient with IBD unspecified\n2. Patient with ileo- or colostomy\n3. Patient with total colectomy\n4. Women that are pregnant","ALL","16 Years",{"count":57,"type":58},100,"ESTIMATED","OBSERVATIONAL","Prospectively study the correlation between Leucine-rich α2-glycoprotein (LRG) and clinical\u002Fendoscopic\u002Fhistological disease activity in patients with inflammatory bowel disease (IBD) in Europe.",[62,63],"Crohn Disease (CD)","Ulcerative Colitis (UC)",[65],"Crohn; ulcerative colitis, LRG, endoscopic remission, endoscopic activity, PRO, quality of life","2026-05-29",{"date":68,"type":69},"2026-06-02","ACTUAL",{"date":71,"type":69},"2026-05-01",{"date":73,"type":58},"2026-12-31",{"name":5,"class":6},1]